Diltiazem HCL is a calcium channel blocker widely used to treat high blood pressure, chronic stable or vasospastic angina, and certain heart rhythm disorders such as atrial fibrillation for rate control. By relaxing blood vessel walls and slowing conduction through the heart’s atrioventricular node, it lowers blood pressure, eases chest pain, and helps regulate heart rate. Available in immediate‑release and extended‑release oral formulations, diltiazem requires individualized dosing and routine monitoring of blood pressure and heart rate. Because it is a prescription-only medication in the United States, consult a licensed clinician to confirm suitability, dosing, and potential interactions before starting therapy.
Diltiazem HCL is a non-dihydropyridine calcium channel blocker that relaxes vascular smooth muscle and slows conduction through the atrioventricular (AV) node. Clinically, it is prescribed to lower high blood pressure (hypertension), reduce the frequency and severity of angina (chest pain) from coronary artery disease or vasospasm (Prinzmetal’s angina), and to control ventricular rate in certain supraventricular arrhythmias, including atrial fibrillation and atrial flutter.
By dilating arteries, diltiazem decreases afterload and myocardial oxygen demand, thereby relieving angina. Its AV nodal effects help slow a fast heart rate in arrhythmias, improving symptoms like palpitations, shortness of breath, or exercise intolerance. Over the long term, blood pressure control with agents like diltiazem reduces the risk of stroke, heart attack, and heart failure. Your clinician chooses diltiazem based on your medical history, other medications, and treatment goals.
Diltiazem is available as immediate-release tablets typically taken multiple times per day and as extended-release capsules or tablets designed for once-daily dosing. The exact brand and formulation matter because bioavailability and maximum doses differ. Always follow the specific directions on your prescription label.
Hypertension and chronic angina (adults): Many clinicians start extended-release diltiazem at 120–180 mg once daily, then titrate at 7–14 day intervals based on blood pressure, heart rate, and symptom control. Typical maintenance ranges are 180–360 mg once daily. Some formulations allow up to 480 mg/day; dosing ceilings vary by product, so do not exceed the maximum listed for your brand without clinician approval.
Immediate-release diltiazem for angina may begin at 30 mg four times daily, titrated every 1–2 days for effect, with common total daily doses of 180–360 mg in divided doses. For rate control in atrial fibrillation, diltiazem dosing is individualized; acute management usually occurs in supervised settings, with oral maintenance guided by resting and exercise heart rate targets.
Administration tips: Take extended-release formulations at the same time each day. Swallow extended-release capsules or tablets whole—do not crush or chew, as this can release the entire dose at once and increase side effect risk. Some capsules can be opened and the beads sprinkled on soft food; only do this if your specific product labeling permits. Take with or without food, but be consistent to keep blood levels stable. Monitor blood pressure and heart rate regularly, especially during titration. Do not abruptly stop diltiazem without medical guidance, as angina may worsen or heart rate may rebound.
Discuss your full medical history, medication list, and supplements with your clinician and pharmacist before starting diltiazem. Because diltiazem can slow heart conduction and lower blood pressure, careful use is necessary in older adults, patients with conduction abnormalities, and those with low baseline blood pressure.
Use caution in heart failure, especially if you have reduced ejection fraction, as non-dihydropyridine calcium channel blockers may worsen symptoms. Patients with liver impairment may require lower doses and more frequent monitoring because diltiazem is extensively metabolized hepatically; rare cases of liver enzyme elevation have been reported. If you have kidney impairment, your clinician will consider dose adjustments and monitor closely.
Pregnancy and lactation: Data in pregnancy are limited; potential benefits should be weighed against risks. Diltiazem is excreted in breast milk—discuss risks and benefits of breastfeeding while taking diltiazem with your clinician. Avoid grapefruit and grapefruit juice, which can raise diltiazem levels and amplify side effects. Until you know how diltiazem affects you, be cautious with activities requiring alertness, as dizziness or fatigue can occur.
Do not use diltiazem if you have a known hypersensitivity to diltiazem or any component of the formulation. It is contraindicated in patients with sick sinus syndrome or second- or third-degree AV block unless a functioning pacemaker is present. Diltiazem should not be used in hypotension (for example, persistent systolic blood pressure below 90 mmHg) or in acute myocardial infarction with pulmonary congestion. Avoid in atrial fibrillation or flutter with an accessory pathway (e.g., Wolff–Parkinson–White) due to risk of accelerating conduction through the accessory tract. Intravenous diltiazem with concomitant IV beta-blockers is also contraindicated.
Most people tolerate diltiazem well. Common side effects include dizziness, headache, flushing, fatigue, and ankle or foot swelling (peripheral edema). Mild gastrointestinal symptoms such as nausea, dyspepsia, or constipation may occur. Some patients experience nasal congestion or a sense of warmth.
Because diltiazem slows AV nodal conduction and lowers blood pressure, bradycardia (slow heart rate), hypotension, and conduction disturbances (first-degree AV block) can occur, particularly at higher doses or when combined with other rate-slowing drugs. Report symptoms of lightheadedness, fainting, shortness of breath, or near-syncope promptly.
Less common effects include rash or pruritus, elevated liver enzymes, gingival hyperplasia (gum overgrowth) with chronic use, and, rarely, clinically significant hepatotoxicity or severe cutaneous reactions. Worsening heart failure symptoms may occur in susceptible individuals. Seek urgent care for severe dizziness, chest pain unrelieved by rest or medication, new or worsening swelling, signs of allergic reaction (hives, facial swelling, wheeze), or yellowing of the skin/eyes.
Diltiazem is metabolized by and inhibits CYP3A4, and it also affects P-glycoprotein. This profile creates important interactions that can increase or decrease drug levels and clinical effects. Always provide your healthcare team with an up-to-date list of prescription drugs, over-the-counter products, and supplements.
Notable interactions include: beta-blockers (e.g., metoprolol, propranolol), which can additively slow heart rate and AV conduction; digoxin, whose levels may rise with diltiazem, warranting monitoring for nausea, visual changes, or bradycardia; and antiarrhythmics such as amiodarone with potential for conduction abnormalities. CYP3A4 substrates like certain statins (simvastatin, lovastatin) can accumulate with diltiazem—dose limits are recommended (for example, keep simvastatin at or below 10 mg/day and lovastatin at or below 20 mg/day when combined). Consider non-CYP3A4 statins (e.g., pravastatin, rosuvastatin) if appropriate.
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) may raise diltiazem concentrations and side effect risk; CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) may reduce diltiazem efficacy. Cyclosporine and tacrolimus levels may increase with diltiazem, requiring dose adjustments. Avoid grapefruit/grapefruit juice. Alcohol can potentiate hypotension. Ask your pharmacist to review your regimen for interaction risks before and after starting diltiazem.
If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose. If it is nearly time for the next dose, skip the missed dose and resume your regular schedule. Do not double up or take extra doses to catch up. For extended-release products, maintaining a consistent daily time improves blood pressure and heart rate control.
Overdose can cause pronounced hypotension, profound bradycardia, AV block, lethargy, confusion, and, in severe cases, shock or cardiac arrest. If an overdose is suspected, call emergency services or a poison control center immediately. Early medical care improves outcomes.
Initial management in a healthcare setting focuses on airway, breathing, and circulation. Supportive measures may include intravenous fluids, atropine for bradycardia, vasopressors for hypotension, and calcium salts to counteract calcium channel blockade. Temporary cardiac pacing may be considered for high-grade AV block. Activated charcoal may be useful if administered soon after ingestion. Because extended-release formulations can prolong toxicity, extended monitoring is often required.
Store diltiazem at room temperature (generally 20–25°C/68–77°F), away from excess heat and moisture. Keep tablets and capsules in their original container with the lid tightly closed and out of reach of children and pets. Do not use past the expiration date, and dispose of unused medication according to local guidance or pharmacy take-back programs.
In the United States, diltiazem HCL is a prescription-only medication. By law, legitimate pharmacies dispense it only with a valid prescription from a licensed clinician, and this safeguard exists to ensure appropriate diagnosis, dosing, interaction screening, and ongoing monitoring of heart rate and blood pressure. Be wary of websites that claim to sell diltiazem “no prescription required” or offer to bypass medical evaluation—such sources can be unsafe, illegal, and may provide substandard or counterfeit products.
HealthSouth Rehabilitation Hospital of Las Vegas supports safe, legal, and convenient access to therapy. Rather than promoting purchases without a prescription, the pharmacy can facilitate care by coordinating with licensed U.S. providers through compliant telehealth pathways when appropriate. This structured approach allows eligible adults to receive an evaluation, obtain a legitimate prescription when clinically indicated, and have genuine, FDA-approved diltiazem dispensed with pharmacist counseling. Transparent pricing, discreet shipping, and ongoing support help patients stay adherent while meeting all regulatory requirements. If you are considering diltiazem for blood pressure, angina, or heart rate control, start by consulting a licensed clinician or use HealthSouth Rehabilitation Hospital of Las Vegas’s patient-first services to connect with one, ensuring your treatment is both effective and compliant with U.S. law.
This article provides general information and is not a substitute for individualized medical advice. Always follow your prescriber’s instructions and speak with a pharmacist if you have questions about your regimen.
Diltiazem HCl is a calcium channel blocker (non‑dihydropyridine) that relaxes blood vessels and slows conduction through the AV node, lowering blood pressure, reducing chest pain (angina), and controlling heart rate in certain arrhythmias like atrial fibrillation.
It is used for hypertension, chronic stable and vasospastic (Prinzmetal) angina, and rate control in atrial fibrillation/flutter and some supraventricular tachycardias.
Immediate‑release begins working within hours; extended‑release once‑daily forms reach steady effect over several days, with full blood pressure benefit often seen in 1–2 weeks.
Take exactly as prescribed; swallow extended‑release tablets/capsules whole unless your specific capsule is labeled as sprinkleable; take consistently with or without food; do not crush or chew extended‑release products.
It comes as immediate‑release tablets (typically 30–90 mg multiple times daily) and extended‑release capsules/tablets (120–420 mg once daily, depending on brand and indication); your prescriber will titrate to response and tolerability.
Dizziness, headache, flushing, fatigue, nausea, ankle swelling (edema), and mild bradycardia are common; constipation can occur but is less frequent than with verapamil.
Severe dizziness or fainting, very slow heartbeat, shortness of breath, new or worsening swelling, chest pain that doesn’t resolve, signs of heart block (extreme fatigue, confusion), or allergic reactions require immediate medical attention.
Avoid if you have severe hypotension, sick sinus syndrome or second/third‑degree AV block without a pacemaker, acute decompensated heart failure or cardiogenic shock, or known hypersensitivity to diltiazem; discuss all heart conditions with your clinician.
Diltiazem is generally avoided in heart failure with reduced ejection fraction because it can worsen pumping function; dihydropyridine CCBs like amlodipine are preferred if a CCB is needed in HFrEF.
It is a moderate CYP3A4 and P‑gp inhibitor; avoid grapefruit; use caution with beta‑blockers (bradycardia/heart block), digoxin (levels may rise), certain statins (limit simvastatin to 10 mg/day), cyclosporine/tacrolimus, DOACs like apixaban/rivaroxaban and dabigatran (bleeding risk), and macrolide antibiotics like clarithromycin (levels rise).
Alcohol can amplify dizziness and blood pressure lowering; limit or avoid and see how you respond before driving or operating machinery.
Take it when you remember unless it’s close to the next dose; do not double up; for once‑daily extended‑release products, if you’re within about 12 hours of the next dose, skip the missed dose and resume the regular schedule.
Monitor blood pressure and heart rate regularly; your clinician may check an ECG for conduction effects and, rarely, liver enzymes during long‑term therapy or if symptoms suggest liver issues.
It is not routinely used in pregnancy unless benefits outweigh risks; it passes into breast milk in small amounts—discuss risks and alternatives with your clinician.
Keep at room temperature, dry, and away from light; store in the original container with the lid tightly closed, and out of reach of children.
Yes, it reduces myocardial oxygen demand and prevents coronary spasm, helping prevent exertional and vasospastic angina episodes; it is for prevention and rate control, not for immediate relief like nitroglycerin.
Peripheral edema is usually benign and dose‑related, but report it; your prescriber may adjust the dose or add an ACE inhibitor/ARB to mitigate it if needed.
Do not stop abruptly; sudden discontinuation can worsen angina or heart rate control; your clinician will guide a taper if discontinuation is appropriate.
Most people can exercise and have sex safely once blood pressure and heart rate are controlled; if you experience dizziness, chest pain, or unusual fatigue, stop and seek medical advice.
It does not typically cause weight gain; apparent weight changes may reflect fluid retention from edema—report persistent swelling or rapid increases in weight.
Both are non‑dihydropyridine calcium channel blockers used for angina, hypertension, and rate control; verapamil causes more constipation and has stronger AV‑node blocking and negative inotropic effects, while diltiazem is often better tolerated with slightly less heart‑rate slowing.
Both lower blood pressure effectively; amlodipine (a dihydropyridine) is purely vasodilatory and once‑daily with fewer conduction effects, but more ankle edema; diltiazem also slows heart rate and may be preferred if you need BP control plus rate control.
Nifedipine ER is a dihydropyridine that lowers BP via vasodilation and can cause reflex tachycardia; it does not slow AV conduction; diltiazem reduces BP and heart rate and is used for arrhythmia control, which nifedipine is not.
Both work; verapamil often produces more potent rate slowing but carries a higher risk of constipation and hypotension; diltiazem is frequently chosen first for a balance of efficacy and tolerability.
Felodipine, like other dihydropyridines, more commonly causes peripheral edema due to arteriolar dilation; diltiazem can cause edema too, but typically at a lower rate.
Oral nicardipine is rarely used chronically; IV nicardipine is used for acute blood pressure control in hospitals; diltiazem is used chronically for hypertension, angina, and AV‑node–mediated arrhythmias, and IV diltiazem is used for acute rate control.
Clevidipine is an ultra‑short‑acting IV dihydropyridine for rapid BP control perioperatively or in hypertensive emergencies; it does not slow heart rate; diltiazem is suitable for rate control and chronic outpatient therapy.
Both lower BP, but isradipine (a dihydropyridine) is less commonly used today; diltiazem may be preferred if heart rate reduction is also desired, whereas isradipine is a pure vasodilator.
Lercanidipine (a long‑acting dihydropyridine not available in all markets) has minimal effect on heart rate; diltiazem reduces heart rate and AV conduction, making it unsuitable when rate slowing is undesirable.
Both help chronic stable and vasospastic angina; amlodipine is excellent for vasospasm and has once‑daily dosing; diltiazem adds rate control and reduces myocardial oxygen demand—choice depends on symptoms, heart rate, and comorbidities.
Diltiazem generally causes less constipation than verapamil due to weaker smooth‑muscle effects in the gut.
Yes, combination therapy is sometimes used for resistant hypertension or angina; monitor for additive edema and hypotension, and avoid combining diltiazem with beta‑blockers without close supervision due to bradycardia risk.
Amlodipine or felodipine may be used if a CCB is necessary; non‑dihydropyridines like diltiazem and verapamil are generally avoided in HFrEF due to negative inotropy.